Clinical Cancer Research Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Y.
Right arrow Articles by Goldman, I. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Y.
Right arrow Articles by Goldman, I. D.
Clinical Cancer Research Vol. 10, 6256-6264, September 15, 2004
© 2004 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Characterization of a Folate Transporter in HeLa Cells with a Low pH Optimum and High Affinity for Pemetrexed Distinct from the Reduced Folate Carrier

Yanhua Wang, Rongbao Zhao and I. David Goldman

Departments of Medicine and Molecular Pharmacology and Cancer Research Center, Albert Einstein College of Medicine, Bronx, New York

Studies were undertaken to characterize a low pH transport activity in a reduced folate carrier (RFC)-null HeLa-derived cell line (R5). This transport activity has a 20-fold higher affinity for pemetrexed (PMX; Kt, ~45 nmol/L) than methotrexate (MTX; Kt, ~1 µmol/L) with comparable Vmax values. The Ki values for folic acid, ZD9331, and ZD1694 were ~ 400–600 nmol/L, and the Ki values for PT523, PT632, and trimetrexate were >50 µmol/L. The transporter is stereospecific and has a 7-fold higher affinity for the 6S isomer than the 6R isomer of 5-formyltetrahydrofolate but a 4-fold higher affinity for the 6R isomer than the 6S isomer of dideazatetrahydrofolic acid. Properties of RFC-independent transport were compared with transport mediated by RFC at low pH using HepG2 cells, with minimal constitutive low pH transport activity, transfected to high levels of RFC. MTX influx Kt was comparable at pH 7.4 and pH 5.5 (1.7 versus 3.8 µmol/L), but Vmax was decreased 4.5-fold. There was no difference in the Kt for PMX (~1.2 µmol/L) or the Ki for folic acid (~130 µmol/L) or PT523 (~ 0.2 µmol/L) at pH 7.4 and pH 5.5. MTX influx in R5 and HepG2 transfectants at pH 5.5 was trans-stimulated in cells loaded with 5-formyltetrahydrofolate, inhibited by Cl (HepG2-B > R5), Na+ independent, and uninhibited by energy depletion. Hence, RFC-independent low pH transport activity in HeLa R5 cells is consistent with a carrier-mediated process with high affinity for PMX. Potential alterations in protonation of RFC or the folate molecule as a function of pH do not result in changes in affinity constants for antifolates. Whereas both activities at low pH have similarities, they can be distinguished by folic acid and PT523, agents for which they have very different structural specificities.




This article has been cited by other articles:


Home page
JNMHome page
C. Muller, R. Schibli, E. P. Krenning, and M. de Jong
Pemetrexed Improves Tumor Selectivity of 111In-DTPA-Folate in Mice with Folate Receptor-Positive Ovarian Cancer
J. Nucl. Med., April 1, 2008; 49(4): 623 - 629.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
A. Qiu, S. H. Min, M. Jansen, U. Malhotra, E. Tsai, D. C. Cabelof, L. H. Matherly, R. Zhao, M. H. Akabas, and I. D. Goldman
Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction
Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1669 - C1678.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
D. T. Thwaites and C. M. H. Anderson
H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine
Exp Physiol, July 1, 2007; 92(4): 603 - 619.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Li, Y.-H. Ling, I. D. Goldman, and R. Perez-Soler
Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non-Small Cell Lung Cancer Cells
Clin. Cancer Res., June 1, 2007; 13(11): 3413 - 3422.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Chattopadhyay, R. G. Moran, and I. D. Goldman
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications
Mol. Cancer Ther., February 1, 2007; 6(2): 404 - 417.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Chattopadhyay, R. Zhao, S. A. Krupenko, N. Krupenko, and I. D. Goldman
The inverse relationship between reduced folate carrier function and Pemetrexed activity in a human colon cancer cell line.
Mol. Cancer Ther., February 1, 2006; 5(2): 438 - 449.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
Y. Wang, A. Rajgopal, I. D. Goldman, and R. Zhao
Preservation of folate transport activity with a low-pH optimum in rat IEC-6 intestinal epithelial cell lines that lack reduced folate carrier function
Am J Physiol Cell Physiol, January 1, 2005; 288(1): C65 - C71.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Zhao, S. Chattopadhyay, M. Hanscom, and I. D. Goldman
Antifolate Resistance in a HeLa Cell Line Associated With Impaired Transport Independent of the Reduced Folate Carrier
Clin. Cancer Res., December 15, 2004; 10(24): 8735 - 8742.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Chattopadhyay, Y. Wang, R. Zhao, and I. D. Goldman
Lack of Impact of the Loss of Constitutive Folate Receptor {alpha} Expression, Achieved by RNA Interference, on the Activity of the New Generation Antifolate Pemetrexed in HeLa Cells
Clin. Cancer Res., December 1, 2004; 10(23): 7986 - 7993.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.